Download presentation
Presentation is loading. Please wait.
Published byDenis Perkins Modified over 9 years ago
1
{ Targeting and killing of malignant gliomas by specific stem cells expressing a suicide gene
2
Gliomas are tumors that arise from glial cells Located in the brain or spinal cord Current treatment: Neurosurgery, Radio- & Chemotherapy After diagnosis, 30% of human patients live to 1 year and 14% live to 2 years. Glioma cells can migrate and form new tumors Malignant Gliomas
3
Have the ability to migrate to a pathological focus (e.g. to brain tumors) Limitations: Cost, low population doublings, ability to subculture, and pathological focus Adult Stem Cells
4
Different types of stem cells were tested and selected for, based on: Ability to be subcultured Highly proliferative No antigenic surface markers Ability to migrate to gliomas and track tumorous cells Bone Marrow-derived Tumor-Infiltrating Cells (BM-TICs) showed the most promise in these experiments Selecting the best cellular vehicle
5
Transduced with a retro-viral vector containing the Thymidine Kinase gene from HSV & the green fluorescent protein gene. Tumor infiltration and ability to track migrating tumor cells Examined by Fluorescence Microscopy BM-TIC genetic modification
6
Gap junction formation? Glioma cells dyed with DiI BM-TICs are dyed with Calcein-AM Intially two distinct populations after mixing (a) Incubated for 3 hours Glioma cells taken in Calcein-AM & BM-TICs have lost intensity DiI is a membrane bound protein Increase in Glioma cells Calcein-AM concentration explained by Gap Junction communication
7
Ganciclovir & Gap Junctions Rats with BM-TIC-tk-GFP injections were treated with Ganciclovir Ganciclovir is a prodrug that reacts with viral thymidine kinase Results in production of a toxic triphosphate Incorporates into DNA and stops replication, signaling apoptosis Gap Junctions between the tumor cells and therapeutic cells allow viral thymidine kinase diffusion Rendering tumor cells susceptible to Ganciclovir
8
In vivo testing Rats were injected with BM-TIC-tk-GFP, into or near tumors 4 days after injection the rats were treated with Ganciclovir daily for 10 days Over 65% of treated rats showed long term survival Statistical significance (P<0.001) % Surviving Animals
9
Future Treatment in humans This method was highly effective in rats and shows promise for the treatment of malignant gliomas in humans Thymidine kinase based gene therapy techniques have reached clinical trials References: Rachet B, Mitry E, Quinn MJ, et alRachet B, Mitry E, Quinn MJ, et al; Survival from brain tumours in England and Wales up to 2001. Br J Cancer. 2008 Sep 23;99 Suppl 1:S98-101 Goodenberger ML, Jenkins RB (2012). “Genetics of adult glioma”. Cancer genet. doi:10.1016/j.cancergen.2012.10.009 Miletic, Hrvoie, et. al. “Bystander Killing Of Malignant Glioma By Bone Marrow-Derived Tumor-Infiltrating Progenitor Cells Expressing A Suicide Gene.” Molecular Therapy: The Journal Of The American Society Of Gene Therapy 15.7 (2007): 1373- 1381.
10
Questions?
Similar presentations
© 2024 SlidePlayer.com Inc.
All rights reserved.